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Incidence and predictors of infection among patients
prior to treatment of chronic lymphocytic leukemia:
a Danish nationwide cohort study 
With the international prognostic index for patients
with chronic lymphocytic leukemia (CLL-IPI), we have a
tool to identify patients with a high risk of progression.1,2
Despite improved supportive care, infections are a signif-
icant cause of morbidity and mortality prior to treatment;
one third of patients with CLL will die following an infec-
tion.3
Though infections in CLL patients have been a subject
of interest in many studies, reporting incidences between
0.13-0.19 per patient-year, there is still no consensus on
how to identify patients who are at an increased risk of
infection. Studies on infectious risk prior to treatment in
CLL are scarce and very heterogeneous in terms of study
populations.4 Consequently, the identification of prog-
nostic markers for risk of infections are warranted. 
Infections in patients with CLL are believed to corre-
late with the progressive immune dysfunction. The pro-
gressive immune dysfunction in CLL is characterized by
a cell-mediated and an antibody-mediated dysfunction.5
The CLL-microenvironmental interaction may play a
major role in this progressive immune dysfunction. The
neoplastic B cells co-evolve together with the microenvi-
ronmental changes, which promotes the leukemia cell
survival and growth while inhibiting normal B-cell and 
T-cell function as well as causing hypogammaglobuline-
mia and cytokine changes.6
The rate, severity and prognostic factors for infections
in CLL prior to treatment constitute a gap in our knowl-
edge of the infection-prone nature of CLL. By means of
the unique Danish National CLL registry, a nationwide
cohort of all patients diagnosed with CLL in Denmark
between 2008 and 2016, and a national Danish
Microbiology database, we conducted a retrospective
study to address this issue.7,8
All patients diagnosed with CLL in Denmark between
January 1st 2010 and July 1st 2016, which was also the end
of follow-up, were included. The CLL-IPI variables and
data on treatment and survival were retrieved from the
Danish National CLL registry.7 Information on
immunoglobulin levels was included if data were avail-
able within six months of diagnosis. Information on
blood cultures was retrieved from the Danish
Microbiology Database.
The event of the first blood culture prior to CLL thera-
py was used as a proxy for severe infection, regardless of
whether an infectious agent was identified. The time to
event was calculated from the date of diagnosis or the
first date of the measurement of immunoglobulin at or
after diagnosis, whichever came last. Patients were fol-
lowed until the date of infection, initiation of CLL-specif-
ic treatment, death or end of follow-up, whichever came
first. Estimates of cumulative incidence for each of the
competing risks were calculated using the Aalen-
Johansen estimator. We examined the difference in the
cumulative incidence of infection using Gray’s test. We
fitted a cause-specific hazard model and a Fine-Gray
model.9 All models were compared to the non-parametric
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Table 1. Cohort description.
All patients Patients included Patients with missing data
n ( %) or median in the multivariable model Number of patients
Characteristic, unit ( range) n (%) or median ( range) with missing data
Number of patients 2905 1204 1701
Age, years 70 (30-98) 69 (32-96) 0
Male sex 1779 (61.0) 719 (59.7) 0
Binet Stage ( B or C ) 516 (18.0) 181 (15.0) 0
Unmutated IGHV (unmutated ) 743 (31.9) 360 (29.9) 573
b-2-microglobulin ( > 4mg/mL ) 330 (14.4) 173 (14.4) 607
del(17p) 148 (6.6) 79 (5.9) 659
IgA ( <0.8 g/L) 389 (19.0) 234 (19.4) 860
IgG ( <6.1 g/L) 342 (16.7) 207 (17.2) 855
IgM ( <0.41 g/L) 948 (46.3) 584 (48.5) 859
Any Ig deficiency 1105 (54,4) 677 (56.3) 864
Cumulative incidence (95 % CI) Cumulative incidence (95 % CI) Cumulative incidence (95 % CI)
5-year cumulative incidence 31.2 (29.0-33.6) 26.0 (22.6-29.4) 34.5 (31.5-37.5) 
of infection (%)
5-year cumulative incidence 21.9 (20.0-24.0) 19.6 (16.7-22.5) 23.3 (20.7-25.9)
of treatment (%)
5-year cumulative incidence 4.9 (3.8-6.0) 3.9 (2.5-5.4) 5.4 (3.9-6.9)
of death (%)
Cohort characteristics of patients in the study and the 5-year cumulative incidences of infection, treatment and death for 1) all patients, 2) patients included in the multi-
variable models, and 3) patients excluded from the analysis. Number of patients with missing data is stated for each variable. Gray’s test showed a significantly higher risk
of infection and treatment for patients missing one or more variable as compared to patients with data available on all variables (P<0.001 and P=0.03), but not for death
(P=0.24). IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M.
Aalen-Johansen curves. Martingale residuals and
Schoenfeld residuals were visualized for diagnostic pur-
poses. Statistical tests were two-sided and P-values of
0.05 were considered significant. All analyses were per-
formed in R. The source code is available on request.
In total, 2905 CLL patients were diagnosed in
Denmark between 2010 and 2016. Of these, 1204
patients had complete data on CLL-IPI variables, sex and
immunoglobulin levels available within six months of
diagnosis. The cohort characteristics of the study popula-
tion are summarized in Table 1. The median age was 70
years old at time of diagnosis, 61% were male. Eighty-
two percent were Binet A, 13% Binet B and 4.7% Binet
C stage. Based on the patients with available CLL-IPI
variables, 55% were low risk (CLL-IPI score 0-1), 30%
were intermediate risk (CLL-IPI score 2-3), 12% were
high risk (CLL-IPI score 4-6) and 2.6% were very high
risk (CLL-IPI score 7-10). Regarding the immunoglobulin
levels, 54% of the patients had immunoglobulin deficien-
cy, with 19%, 17% and 46% having low levels of
Immunoglobulin A (IgA), Immunoglobulin G (IgG) and
Immunoglobulin M (IgM), respectively. 
In the entire cohort of 2905 patients, a total of 1239
patients had an event; an infection, treatment initiation
or death. The median follow-up time was 2.9 years (IQR:
1.53-4.57). Having a blood culture drawn prior to treat-
ment or death was the most common event, which
occurred in 662 patients; 482 patients received treatment
without first having had an infection, and 95 patients
died without having had an infection or having received
treatment. The cumulative incidence of infection prior to
treatment was 12% after one year. For treatment initia-
tion prior to having a blood culture drawn, the cumula-
tive incidence was 11% after one year, and 1% after one
year for death prior to treatment or infection (Table 1 and
Figure 1). Of the patients with an infection, 65 patients
(9.8%) died within 30 days after the infection, 163 (25%)
died within one year after the infection and 74 (11%)
received treatment for CLL within one year.
A significantly higher risk of infection was demonstrat-
ed for the following variables: 1) older compared to
younger patients (P<0.001), 2) male patients (P=0.02), 3)
patients with Binet stage B or C (P=0.04), 4) patients with
unmutated IGHV (P=0.04), 5) patients with high levels of
b-2-microglobulin (B2M>4mg, P<0.001), 6) patients with
low levels of IgA (P=0.004), 7) patients with low levels of
IgG (P=0.009), and 8) patients with low levels of IgM
(P=0.008) (Online Supplementary Figure S1). We fitted mul-
tivariate models on data from 1204 patients with all vari-
ables available. The cumulative incidences of infection,
treatment and death for these patients were somehow
lower than for patients with missing variables (Table 1). 
The cause-specific hazard and Fine-Gray models are
summarized in Table 2 for all three competing outcomes.
From the cause-specific model, we found that patients
with low IgA levels compared to those with normal/high
IgA levels had a hazard rate for infection of 1.61; 95 %
cumulative incidence (CI; 1.19-2.19); P<0.001. For the
variables age, sex, Binet stage and B2M the hazard rates
were estimated as 1.03 per year; 95% CI (1.01-1.04); 
P< 0.001, 1.38; 95% CI (1.05-1.81); P=0.02, 1.73; 95% CI
(1.24-2.41); P<0.001 and 1.46; 95% CI (1.03-2.09);
P=0.04, respectively.
In this nationwide cohort, we assessed the incidence
and prognostic factors for infections prior to any CLL
treatment as well as the outcomes after such infections in
patients prior to treatment of CLL. Severe infections were
very common prior to treatment, with a five-year cumu-
lative incidence of 31% among 2905 CLL patients. Age,
sex, Binet stage, B2M and IgA levels were significantly
associated with the cause-specific hazards rate of infec-
tion. 
Compared to previously published studies, we present
herein the largest and most homogeneous cohort for
analysis of prognostic factors for risk of infection. We did
not find del(17p) nor unmutated IGHV to be associated
with the rate of infection. This might be due both to the
small numbers of patients with del(17p) and the fact that
these prognostic factors are highly associated with the
risk of treatment, thus, in a competing risk scenario they
do not correlate with infection before treatment (Table
2).
For this registry-based study, we used the event of a
blood culture as a proxy for the event of a severe infec-
tion. According to the Danish national guidelines, a
blood culture is drawn when a sepsis is suspected, and
the patients should always receive intravenous antibi-
otics afterwards.10 The herein demonstrated cumulative
incidence of severe infection in patients with untreated
CLL within the first year after diagnosis of 12% is within
the range of previously reported 0.13-0.19 infections per
patient-year.5 The previously reported rates allow multi-
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Figure 1 Cumulative incidence for all out-
comes. Aalen-Johansen cumulative inci-
dence estimates for the three outcomes
stacked on top of each other. Each patient
could only have one event, that being
whichever came first. Thus, infections sub-
sequent to treatment and vice versa were
not included. Time zero is the time of diag-
nosis for all patients. 
ple events per patient-year while the cumulative inci-
dence only counts one event per patient, which may
explain the slightly lower rate in our study. Moreover, we
only included untreated patients, who have a lower
infectious burden.5 The 30-day post-infection mortality
rate of 9.8% demonstrated herein is comparable to a pre-
vious study on hematological malignancies.11
Immunoglobulin deficiency is common at diagnosis
and occurs spontaneously throughout the natural course
of the disease and is related to disease duration and
stage.12 In this study we found IgA to be the best predic-
tor of the rate of infections, however IgG and IgM were
also associated with the rate of infection in the univariate
analysis. IgA is especially important on mucosal surfaces
where it binds and prevents translocations of
pathogens.13 Most patients with IgA deficiency are
asymptomatic, and the IgA mucosal immunity is often
considered superfluous.13 When multiple facets of the
immune system are dysfunctional, e.g., in CLL, IgA may
either play a greater role itself in protection, or it may
merely serve as a proxy for the degree to which the CLL
cells inhibit the immune system. Sun et al. showed that
upon treatment with ibrutinib, patients experienced an
increase in IgA. After six months, patients had fewer
infections although their levels of IgG remained low,
while the decrease in infectious risk correlated with
improved IgA levels in the study herein.14
Due to the registry-based design, we did not have any
information on comorbidities. As multiple medical condi-
tions add to the infectious risk of patients with CLL, we
were unable to assess whether this confounded our
results. The lack of data on comorbidities may overesti-
mate the role of aging rather than recognizing the rele-
vance of comorbidities.15 
The data presented herein thus represent the first step
for identification of further risk factors for infection at
time of CLL diagnosis. Exploration of prophylactic or pre-
emptive treatment strategies for this population in clini-
cal trials is warranted. This should also include investiga-
tion of risk factors for infections in treated patients.
Validation of the herein presented data in independent
cohorts is encouraged. 
Online Supplementary Information is available on
Haematologica's website.
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Table 2. Results of the regression models. 
A) Cause-specific proportional hazard regression model
Infection Treatment Death
HR Lower CI Upper CI P HR Lower CI Upper CI P HR Lower CI Upper CI P
Age, per year 1.03 1.01 1.04 0.00 0.99 0.98 1.01 0.23 1.08 1.04 1.13 0.00
Male sex 1.38 1.05 1.81 0.02 1.03 0.75 1.40 0.87 1.27 0.61 2.62 0.52
Binet B or C 1.73 1.24 2.41 0.00 4.20 3.06 5.75 0.00 0.50 0.12 2.14 0.35
U-IGHV 1.29 0.97 1.71 0.08 3.30 2.42 4.49 0.00 0.66 0.27 1.65 0.38
del(17p) 1.05 0.59 1.90 0.86 2.02 1.18 3.47 0.01 1.79 0.59 5.39 0.30
B2M (> 4mg/mL) 1.46 1.03 2.09 0.04 1.69 1.16 2.45 0.01 2.68 1.14 6.26 0.02
IgA < 0.80 g/L 1.61 1.19 2.19 0.00 2.18 1.59 3.01 0.00 1.53 0.67 3.53 0.31
B) Fine-Gray regression model
Infection Treatment Death
HR Lower CI Upper CI P HR Lower CI Upper CI P HR Lower CI Upper CI P
Age, per year 1.03 1.01 1.04 0.00 0.99 0.98 1.00 0.16 1.07 1.03 1.12 0.00
Male sex 1.37 1.04 1.80 0.02 0.96 0.69 1.32 0.79 1.20 0.58 2.49 0.62
Binet B or C 1.30 0.92 1.84 0.14 3.68 2.63 5.14 0.00 0.33 0.08 1.30 0.11
U-IGHV 1.08 0.81 1.44 0.59 3.08 2.23 4.25 0.00 0.52 0.20 1.39 0.19
del(17p) 0.83 0.46 1.51 0.55 1.66 0.94 2.93 0.08 1.90 0.61 5.94 0.27
B2M (> 4mg/mL) 1.25 0.87 1.80 0.24 1.54 1.03 2.32 0.04 2.28 1.03 5.03 0.04
IgA < 0.80 g/L 1.39 1.02 1.89 0.04 1.82 1.30 2.57 0.00 1.28 0.59 2.77 0.52
Results of the A) cause-specific proportional hazard regression models and B) Fine-Gray regression models for CLL with infection, treatment and death as outcomes. U-
IGHV: unmutated IGHV; B2M: b-2-microglobulin; HR: hazard ratio; CI: cumulative incidence.
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